Format

Send to

Choose Destination
Anticancer Res. 2015 Oct;35(10):5615-21.

What Predicts Minimal Response to Abiraterone in Metastatic Castrate-resistant Prostate Cancer?

Author information

1
Velindre Cancer Centre, Cardiff, Wales, U.K. rhian.s.davies@wales.nhs.uk.
2
Velindre Cancer Centre, Cardiff, Wales, U.K.
3
Velindre Cancer Centre, Cardiff, Wales, U.K. Institute of Cancer Genetics, Cardiff University, Cardiff, Wales, U.K.

Abstract

BACKGROUND:

Several treatments have been shown to prolong survival in metastatic castrate-resistant prostate cancer (mCRPC); the optimum sequencing of these is not established. We investigated methods of identifying patients with mCRPC unlikely to respond to abiraterone.

PATIENTS AND METHODS:

A retrospective analysis was carried-out in 47 consecutive patients with mCRPC treated sequentially with androgen deprivation (LHRHa), bicalutamide, docetaxel then abiraterone.

RESULTS:

The median progression-free survival in patients treated with abiraterone was shorter in those with ≤18 months' response to LHRHa (118 vs. 279 days; p=0.018), bicalutamide non-responders (91 vs. 196 days; p=0.003) and patients with ≤6 months' response to docetaxel (102 vs. 294 days; p<0.001). The median overall survival was also shorter (348 vs. 815 days, p=0.016; 413 vs. 752 days, p=0.009; and 325 vs. 727 days, p<0.04, respectively).

CONCLUSION:

A response of ≤18 months' to LHRHa, non-response to bicalutamide and ≤6 months' response to docetaxel predicted poor response to abiraterone.

KEYWORDS:

Metastatic; abiraterone; castrate-resistant; drug sequencing; predictors response; prostate cancer

PMID:
26408734
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center